Abivax SA

詳細情報 Abivax SA 企業名

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

企業情報

企業コードABVX

会社名Abivax SA

上場日Jun 26, 2015

最高経営責任者「CEO」Mr. Marc De Garidel

従業員数- -

証券種類Ordinary Share

決算期末- -

本社所在地7-11 Boulevard Haussmann

都市PARIS

証券取引所Euronext Paris

国France

郵便番号75009

電話番号33153830963

ウェブサイトhttps://www.abivax.com/

企業コードABVX

上場日Jun 26, 2015

最高経営責任者「CEO」Mr. Marc De Garidel

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Patrick Malloy

Head of Investor Relations

--

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

--

Mr. Michael Ferguson

Chief Commercial Officer

--

Mr. Didier Bruno Blondel

Chief Financial Officer, Board Secretary

--

Mr. Troy A. Ignelzi

Independent Director

--

Dr. Fabio Cataldi, M.D.

Chief Medical Officer

--

Ms. Ana Sharma

Vice President - Global Head of Quality

--

Ms. Corinna Zur Bonsen-Thomas

Independent Director

--

Mr. Pierre Courteille

Chief Business Officer

--

Ms. Ida Hatoum

Chief People Officer, Chief Compliance Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Patrick Malloy

Head of Investor Relations

--

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

--

Mr. Michael Ferguson

Chief Commercial Officer

--

Mr. Didier Bruno Blondel

Chief Financial Officer, Board Secretary

--

Mr. Troy A. Ignelzi

Independent Director

--

Dr. Fabio Cataldi, M.D.

Chief Medical Officer

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sun, May 18

株主統計

種類

株主統計

比率

TCG Crossover Management, LLC

8.23%

Deep Track Capital LP

4.86%

Adar1 Capital Management LLC

3.00%

Cormorant Asset Management, LP

2.90%

Great Point Partners, LLC

2.23%

Other

78.78%

株主統計

比率

TCG Crossover Management, LLC

8.23%

Deep Track Capital LP

4.86%

Adar1 Capital Management LLC

3.00%

Cormorant Asset Management, LP

2.90%

Great Point Partners, LLC

2.23%

Other

78.78%

種類

株主統計

比率

Hedge Fund

23.84%

Investment Advisor

10.96%

Investment Advisor/Hedge Fund

3.77%

Venture Capital

2.49%

Research Firm

2.19%

Other

56.74%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

74

31.84M

43.27%

-317.18K

2025Q1

74

31.82M

50.18%

-39.44K

2024Q4

67

29.91M

47.53%

+1.67M

2024Q3

53

27.43M

43.59%

-1.47M

2024Q2

50

28.12M

44.69%

-980.96K

2024Q1

45

23.37M

37.15%

+1.78M

2023Q4

32

21.64M

34.39%

+20.54M

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

TCG Crossover Management, LLC

6.06M

9.55%

--

Mar 31, 2025

Deep Track Capital LP

3.58M

5.64%

--

Mar 31, 2025

Adar1 Capital Management LLC

2.21M

3.48%

+696.63K

+46.03%

Mar 31, 2025

Cormorant Asset Management, LP

2.13M

3.36%

--

Mar 31, 2025

Great Point Partners, LLC

1.64M

2.58%

-10.41K

-0.63%

Mar 31, 2025

Nantahala Capital Management, LLC

1.48M

2.34%

+46.95K

+3.27%

Mar 31, 2025

Citadel Advisors LLC

1.37M

2.17%

+518.18K

+60.56%

Mar 31, 2025

Franklin Advisers, Inc.

1.37M

2.16%

-95.01K

-6.48%

Mar 31, 2025

VR Adviser, LLC

1.35M

2.12%

--

Mar 31, 2025

Caligan Partners, LP

1.27M

2%

+516.95K

+68.73%

Mar 31, 2025

詳細を見る

71.420USD

Abivax SA

71.420

概要

企業名

金融